CAS |
No.349085-82-1 |
中文名称 |
4-甲氧基-N-(2,4,6-三甲基苯)苯磺酰胺 |
英文名称 |
GSK137647A |
别名 |
GSK137647 |
分子式 |
C16H19NO3S |
分子量 |
305.39 |
溶解性 |
Soluble in DMSO |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
货期 |
1-2个工作日 |
MDL |
MFCD02007969 |
SMILES |
O=S(C1=CC=C(OC)C=C1)(NC2=C(C)C=C(C)C=C2C)=O |
InChIKey |
FQUAFMNPXPXOJE-UHFFFAOYSA-N |
InChI |
InChI=1S/C16H19NO3S/c1-11-9-12(2)16(13(3)10-11)17-21(18,19)15-7-5-14(20-4)6-8-15/h5-10,17H,1-4H3 |
PubChem CID |
743974 |
靶点 |
GPR120;FFA4 |
通路 |
GPCR & G Protein |
背景说明 |
GSK137647A是一种选择性FFA4激动剂。 |
生物活性 |
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively.GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response[1][2]. |
In Vitro |
GSK137647A (GSK 137647) (50 μM) reduces the production of NO in macrophages without affecting cell viability[1].GSK137647A (GSK 137647) (30 μM; 12 hours) alleviates response to inflammatory stimuli in Caco-2 cells and induces secretion of IL-6[1].GSK137647A (GSK 137647) (10 μM) reduces the ion flow and affects the colonic epithelial ion transport in healthy[1].GSK137647A (GSK 137647) (50 μM) increases glucose stimulated insulin secretion[2].Western Blot Analysis[1]:Cell Line:Caco-2 cells;Concentration:30 μM;Incubation Time:12 hours;Result:Downregulated FFAR1, FFAR2, and FFAR4 as compared to control.Cell Viability Assay[1]:Cell Line:RAW264.7 macrophages;Concentration:10, 20 and 50 μM;Incubation Time: 24 hours;Result:Without affected cell viability. |
In Vivo |
GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) alleviates colitis in TNBS- and DSS-treated mice[1].GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) restores intestinal permeability in vivo[1].Animal Model:Male C57BL/6 mice[1];Dosage: 1 mg/kg;Administration:Intraperitoneal injection; twice daily, for 7 days;Result: Had anti-inflammatory effect and reversed colonic injury induced by DSS.Animal Model:Male C57BL/6 mice[1];Dosage:1 mg/kg;Administration:Intraperitoneal injection; twice daily, for 7 days;Result:Decreased the amount of FITC and alleviated intestinal epithelial barrier permeability. |
数据来源文献 |
[1]. Salaga M, et, al. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. [2]. Sparks SM, et, al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul 15;24(14):3100-3. |
规格 |
5mg 10mM*1mL in DMSO 10mg 25mg 50mg |
单位 |
瓶 |